Perceptive Automata named one of the best companies to work for second year in a row – PR Web

BOSTON (PRWEB) January 14, 2021

Perceptive Automata, the leading provider of human behavior understanding AI for machines, has been named one of the 100 Best Places To Work and 50 Best Small Companies To Work For in Boston by Built In. The annual awards include companies of all sizes - nationally and in the eight largest tech markets.

We are extremely proud to be recognized as one of the Best Workplaces in Boston, said Bruce Reading, CEO at Perceptive Automata. We take great pride in cultivating an inclusive work environment and culture that allows employees to thrive. Our success is rooted in our ability to inspire talented people to join, engage and grow within our company, by creating a supportive and engaging workplace for all.

Fostering a comfortable work environment with a strong sense of community is a core component of the culture at Perceptive Automata. Perceptive Automata believes that people are at their best doing cognitively demanding and fulfilling work when they are rested and at ease. Allowing flexible working hours, taking group lunch breaks together (prior to the COVID-19 pandemic), and blowing off steam after hours with activities including virtual game nights and cocktail making classes help support our relaxed and community focused culture. Investing in each employee is a priority at Perceptive Automata. Team members have the opportunity to take supplementary courses, participate in academic conferences and industry workshops relevant to their role, fully funded by the company. Additionally, Perceptive Automata brings in different trainings on a quarterly basis for the entire team to help develop them throughout their career with the company.

This recognition from Built In follows a year of substantial growth and product innovation for Perceptive Automata, including receiving an AUVSI XCELLENCE Award and a 2020 World Changing Ideas Finalist award from Fast Company.

Built In determines winners for Best Places to Work based on an algorithm, using company data about benefits, cultural programs, and compensation. To reflect the attributes candidates are searching for on Built In today, this years program weighted criteria more heavily, like remote opportunities and programs for diversity, equity and inclusion.

About Perceptive AutomataPerceptive Automata is creating a best-in-class artificial intelligence that gives machines, such as self-driving cars, the ability to understand the human state of mind. The company combines behavioral science techniques with machine learning to give autonomous systems the capability to anticipate and react to human behavior, enabling autonomous vehicles to navigate safely and smoothly around pedestrians, cyclists, and other drivers. This is essential for autonomous systems to seamlessly roll out in human-dominated road environments and to deliver a smooth ride experience for passengers of autonomous mobility services. For more information about Perceptive Automata, visit http://www.perceptiveautomata.com.

Share article on social media or email:

Original post:
Perceptive Automata named one of the best companies to work for second year in a row - PR Web

Brain & Behavior Research Foundation Receives $8 Million Bequest from Philanthropist and Mental Health Advocate Stephen Lieber – GlobeNewswire

Stephen Lieber

Dr. Jeffrey Borenstein, Stephen Lieber, Dr. Herbert Pardes, Constance Lieber

New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that is has received a bequest of $8 million from the noted philanthropist and mental health advocate Stephen Lieber. The Foundation is the worlds largest private funder of mental health research grants, and this gift will be used to expand its support for research that is transforming the lives of people living with mental illness.

Mr. Lieber, who died in 2020, and his wife Connie, who died in 2016, made a lifetime commitment to advancing scientific research on the brain and mental health with the goal of reducing human suffering caused by severe psychiatric disorders. Their efforts have launched thousands of careers in mental illness research, including support to leading scientists at renowned institutions around the world, that has led to countless discoveries in the field of biological psychiatry and related patient services. In fact, the vast majority of major scientific investigators studying the brain and human behavior have received Lieber philanthropic support.

The Lieber Prize for Outstanding Achievement in Schizophrenia Research is one of the most coveted prizes in the field. To date, two Lieber Prize winners have gone on to win Nobel Prizes.

Steve and Connie were leading public advocates and philanthropic supporters of schizophrenia, depression, and mental health research in the U.S. and around the globe, said Herbert Pardes, M.D., President of the Brain & Behavior Research Foundations Scientific Council and Executive Vice Chair of the Board of Trustees of NewYork-Presbyterian Hospital. They were an amazing couple and remarkable in every way.

In the mid-1980s, Dr. Pardes introduced the couple to the organization that became the Brain & Behavior Research Foundation (BBRF), which they joined in 1987 and which Connie led as president until 2007, and Steve served as Chairman of the Board from 2008 until his death.

Our meeting more than 30 years ago resulted in a major step forward in the global effort to treat and cure psychiatric disease, Dr. Pardes noted. With Connie and Steves support, the Brain & Behavior Research Foundation developed a uniquely warm, understanding and empathic approach to the patients, families and investigators of the broad mental health community. We are incredibly grateful for this latest contribution and the noble leadership and friendship of the Liebers over many decades.

This significant donation is especially welcomed at a time when the stresses of COVID-19 have further highlighted the need for greater attention to mental health, noted Dr. Jeffrey Borenstein, President & CEO of the Brain & Behavior Research Foundation. Steve was a deeply passionate and visionary philanthropist, and along with his late wife Connie, had a tremendous impact on psychiatric research and treatment. For more than a quarter of a century, Steve and Connie served as extraordinary philanthropic supporters and leading public advocates of brain and behavior research. They provided unwavering support to unravel the mysteries of the brain, and to better understand and treat mental illness. Together, they mobilized every resource imaginable to fund cutting-edge research and educate the public, tirelessly working to grow the BBRF grant program. Their generosity in supporting research on mental illness is a great model for all of us.

In 2014, Steve and Connie Lieber were honored by the American Psychiatric Association with a Special Presidential Commendation for their unwavering moral and material support to unravel the mysteries of the brain, and to better understand and treat mental illness. Also, in 2014, the Liebers created the Pardes Humanitarian Prize in Mental Health to honor those scientists and humanitarians who comprehensively care, teach, investigate, work, and passionately advocate for improving the mental health of society and reducing the pain of psychiatric illness.

In addition to their work with BBRF and many other mental health institutions, the Liebers founded two centers of excellence at Columbia University the Lieber Recovery and Rehabilitation Clinic and the Lieber Center for Schizophrenia Research and Treatment, as well as the Lieber Institute for Brain Development at Johns Hopkins University. Steve Lieber, who was an investment executive for 70 years, also endowed the neuroscience department at his alma mater, Williams College.

The Brain & Behavior Research FoundationThe Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $418 million to fund more than 6,000 leading scientists around the world, which has led to over $4 billion in additional funding. 100% of every dollar donated for research is invested in research. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Originally posted here:
Brain & Behavior Research Foundation Receives $8 Million Bequest from Philanthropist and Mental Health Advocate Stephen Lieber - GlobeNewswire

The Public Should Regulate Silicon Valley Not the Other Way Around – Jacobin magazine

Donald Trumps Twitter ban is a poetic end to his performance.

In 2016, the outsider-insider outmaneuvered his enemies and seized power with the aid of an aggressive, nimble base stitched together online. Now the failing God-Emperors soliloquy is silenced by the very force who helped him come to power, amid the tragicomic denouement of armed furries and blood on the Capitol floor.

But beneath the aesthetics lie the politics. Twitter birthed Trump, giving him a platform that incentivized his every behavior. A format where 280-character zingers replace serious debate, conflict is rewarded, and attack mobs form and dissipate at light speed was always fertile ground for the hard right. A blank-slate AI became a neo-Nazi within twenty-four hours of Twitter exposure.

Trump and Twitter both offer the promise of popular power and participation whilst strengthening existing social relations and ordering them to extract further profit. Facebook is less theatrical and more intimate, but equally prone to rapid poisoning, as anyone who has witnessed the conversion of a mild-mannered local history forum into an explosion of nativist racism can attest.

The problem for the tech giants is that after Trump, such criticism went mainstream. Until the post-recession unravelling of politics, the Californian Ideologys combination of the free-wheeling spirit of hippies and the entrepreneurial zeal of yuppies had positioned Big Tech benignly. They were in deep with the deep state, undoubtedly knowing more about information warfare than Pentagon generals. And yet they were simultaneously championing libertarian free expression; creating democratized spaces where if enough of you yelled at your leaders from your bedrooms, those leaders may even be compelled to respond.

But after Brexit and Trumps 2016 win, things changed. From democratic socialist Alexandria Ocasio-Cortez to centrist Conservative Damian Collins in the UK, politicians hauled in tech bosses for highly public grillings. They were made to account for why their biomes had spawned hives of hatred and misinformation into the body politic. In this space, deeper layers of critique opened up on all sides.

Richard Seymours The Twittering Machine and Wendy Lius Abolish Silicon Valley challenged techs practices from the Left. Shoshana Zuboffs bestseller argued that the Big Four had mutated capitalism itself. Thirty-eight million people watched The Social Dilemma, where experts sounded the alarm on their own creations. On the right, the UKs Daily Telegraph, who had backed the Brexit campaign and its unprecedented use of social technology, begun blaming tech giants for social ills like poor teenage mental health. Suddenly the Zuckerbergs and Dorseys faced a withering triple barrage of conservative anti-modernity, liberal panic about disorder and demagoguery, and socialist opposition to unfettered capitalism.

Silicon Valley are strategists first and foremost. They concentrate technical expertise to leverage huge quantities of raw information into commercial success, through product innovation but also through general political and market interventions. By the end of the decade their lowest-cost strategy was an alliance with liberalism.

Rhetorical commitments to racial justice and gender equality came cost-free (except for igniting the ire of right-wingers who would then use social media networks to berate them, creating profitable rows.) Many like Facebook COO Sheryl Sandberg were already ideologically committed to a superficial politics of equality, and in fairness were probably genuinely repulsed by the Trumpian far right. The polls were beginning to swing for Joe Biden. All roads were leading to a rapprochement with liberalism, a long-overdue partial clampdown on fascists, and turning on Trump.

These strategies are not merely about survival but increasing power. Zuboff describes lucidly how tech firms have repeatedly implemented coup tactics; suddenly staking an unprecedented claim on something, defining it as the new normal, and taking advantage of public / political ignorance of both existing technologies and plausible alternatives.

In normal circumstances, denying a world leader access to mass communication would be seen as shocking. In circumstances where said leader has just worked up a mob to smash its way across the shining hill of the foremost world power, there was a unique opportunity to lever much of liberalism and the Left into accepting and even applauding the precedent being established.

The giants have gone from risking being pariahed by all sides of politics, to accepting the mantle of arbiter of truth from grateful politicians and commentators. This dynamic is not just at risk of being used against the Left and anyone else deemed outside a narrow zone of acceptability. It is already being used against the Left.

In the United States, Instagram recently flagged as false a post containing political comment about the 1994 Crime Bill and its links to carceral racism. In the UK, left-wing MP Zarah Sultanas criticism of the Conservative governments (lack of) COVID-19 strategy has spuriously been labeled as fake news.

Trumps register is uniquely developed for Twitter, and the insurgent right benefits from using social media to grow their communities and outfox mainstream operators. But they also have huge cash reserves and control of news networks. The Left depends far more on social media for organizing and mass communication in the context of both fewer financial resources, and legacy media which largely refuses to treat leftists seriously or fairly.

Banning Trump is Twitters strategic masterstroke. Do you have a problem with how digital communication is being used? Any conversation about genuine democratization or accountability of mass communication is off the table; the only possible solution offered is to cede more power to people who are interested in no less than shaping and directing the totality of human behavior.

This does not answer the question was Twitter right to ban Trump? But that is not a particularly interesting question in itself. Perhaps the ban is justified, it is certainly ironically amusing. The context in which it takes place; and the new assumption that this system is how such incidents are to be resolved, is much more concerning.

There is a line given by a senior Bush White House staffer in a candid anonymous interview in the 2000s which achieved cultural infamy when quoted in a 2017 album by The National.

You believe that solutions emerge from your judicious study of discernible reality. Thats not the way the world really works anymore. Were an empire now, and when we act, we create our own reality. And while you are studying that reality well act again, creating other new realities. Were historys actors, and you, all of you, will be left to just study what we do.

The message captures the approach taken by Trump, by tech firms and other capitalists, and by many more political actors that is, an attempt to use the current period of chaos to make rapid incursions and impose new realities.

Silicon Valley, as guardian of public discourse, is one such new reality, and those breathing a sigh of relief that the democratic crisis is over with the self-defeat of the QAnon putsch are breathing far too soon. In the wreckage of that putsch is a centrism which has developed ever more authoritarian tendencies, a belligerent Trumpism that has no interest in accepting defeat, and a technical elite who have staked a bold new claim to both defining and enforcing truth. It is an environment in which right-wing anti-democrats of all shades can thrive.

Original post:
The Public Should Regulate Silicon Valley Not the Other Way Around - Jacobin magazine

Study On Rabbit Brain Reveals Genetic Markers Of Domestication – Texas A&M University Today

Tolerance of humans and tameness are noted traits differentiating domestic and wild rabbits.

Getty Images

An international team of researchers led by Leif Andersson, a professor at the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS), has found changes in gene expression patterns across the brain between wild and domestic rabbits, which likely contributed to the evolution of tameness during domestication.

By demonstrating that domestic animals acquired tolerance toward humans through regulatory changes of certain genes, researchers are able to better understand the link between genetic changes and the mechanisms of evolution in rabbits and, at a larger scale, of plants and animals in general. The research builds off Anderssons previous work demonstrating a link between rabbit domestication and brain structure.

The European rabbit is one of the most recently domesticated animals, exhibiting distinct morphological, physiological and behavioral differences from their wild counterparts. Tolerance of humans and tameness are noted traits differentiating the domestic and wild rabbits.

Domestication is often associated with the rapid development of such traits in a rather short evolutionary time period. As such, domestication has long been a major topic in evolutionary biology, as it allows researchers to study the mechanisms of evolution on a more manageable time scale.

In the study, published in Genome Biology and Evolution, the researchers compared gene expression patterns in four brain regions between newborns of wild and domestic rabbits. They detected hundreds of genes differentially expressed between the two.

It is important to notice that the drastic changes in behavior between domestic animals and their wild ancestors are associated with changes in how genes are expressed during the development of the brain, Andersson said. The domestication of plants and animals is one of the most important developments during human history. In this study, we shed light on how this process has altered brain function in domestic animals and made them tamer.

One significant finding was that genes involved in dopamine signaling, a chemical involved in fear responses, were expressed at higher rates in the amygdala, or area of the brain associated with memory, decision-making, and emotional responses, of the domestic rabbit. Notably, the amygdala is known as the part of the brain driving the fight or flight response, which would play a part in determining whether a wild animal flees in the company of humans or a tame animal tolerates human presence.

Researchers also found that genes associated with ciliary function were consistently downregulated in the hippocampus, an area of the brain associated with learning and memory, of domestic rabbits. Cilia cells are tiny hair-like structures that aid in the circulation of cerebrospinal fluid.

The flow of this fluid contributes to the transmission of molecular signals across the brain. Since these ciliary genes are important for brain development, the researchers hypothesized that these changes contribute to the evolution of tameness.

We were really surprised by the consistent changes we observed that several genes involved in dopamine signaling were consistently unregulated in the domestic brain, and that many genes with associated with ciliary function was consistently downregulated, Andersson said.

View post:
Study On Rabbit Brain Reveals Genetic Markers Of Domestication - Texas A&M University Today

Nearly a Quarter of Americans 21 To 50 Years Old to Consider Having Children if Fertility Treatments Are More Affordable, Says Fertility Access Survey…

SAN FRANCISCO, Jan. 13, 2021 /PRNewswire/ -- Nearly a quarter of Americans 21 to 50 years old would consider having children if fertility treatments are more affordable, according to the Fertility Access Survey conducted by Engine Insights on behalf of Lane Fertility Institute.

The survey finds that 23 percent of Americans in this age range, who do not already have children living at home, would consider having kids if access to fertility treatments is more affordable, with more women (24 percent) than men (21 percent) saying so.

From an annual household income perspective, respondents who earn less than $100,000 (41 percent) are more likely than those who earn $100,000 or more (35 percent) to consider having children with more affordable access to fertility treatments.

Drilling down even further, 21 percent of American households that earn less than $50,000 a year would consider having kids with more affordable access to fertility treatments, compared with 20 percent of households earning $50,000 to $100,000 a year.

Looking at race, the survey finds that 22 percent of African Americans, compared with 18 percent of white survey respondents, would consider having children if they received affordable access to fertility treatments.

On another note, 31 percent of married respondents say they would think about having children with more affordable access to fertility treatments, versus only 20% of those who are not married.

"As more people wait until later in life to have children, the need for affordable access to fertility treatments is growing exponentially," says Danielle Lane, M.D., who specializes in fertility medicine at her San Francisco Bay Area-based practice, Lane Fertility Institute. "Fertility treatments shouldn't only be an option for the rich and those who have stellar health benefits. We need to provide solutions for people from all income levels, races and other socioeconomic factors that influence who receives access to fertility treatments.

"The moral imperative is on us, as medical professionals, to provide quality access to affordable fertility treatments for those who choose to maximize their career potential, or perhaps wait longer to meet the right partner, before starting their families. We never want finances to stand in the way of anyone pursuing their dream of having a family."

The Cost of Fertility Treatments

In vitro fertilization (IVF) is among the most common types of fertility treatments, which can range from $10,000 to $15,000 per cycle. Other treatments include receiving a donor egg that can cost $30,000 to $50,000, and egg freezing, which costs as much as $10,000 to provide women with access to their eggs later in life.

Dr. Lane says a couple of decades ago, it made sense that fertility treatments cost a lot more than the average person could afford since the technology and access to fertility doctors were still emerging.

"Today, fertility doctors and treatments are relatively mainstream, and yet the cost of access is prohibitive, particularly among lower-income households and people who do not have health plans that cover these treatments," Dr. Lane says.

Another cost-effective alternative to IVF is INVOcell, which is a medical grade device that develops embryos within a woman's body instead of an embryology lab. The treatment can be a fraction of the cost of traditional IVF.

Dr. Lane says "shared donor cycles" are also a way to minimize costs by allowing two or more separate sets of intended parents to share the costs involved with retrieving and utilizing eggs from an egg donor, providing access to half of the eggs for each set of intended parents.

"Understanding your options should be a priority when considering fertility treatments," Dr. Lane says. "Talking to your doctor about cost-effective solutions is critical to building your family if finances are a concern."

Fertility Access Survey Methodology

The Fertility Access Survey was conducted by ENGINE INSIGHTS among a sample of 692 adults 21 to 50 years of age who do not have any children under 18 living at home. The online omnibus study is conducted three times a week among a demographically representative U.S. sample. This survey was live the week of January 4, 2021.

To view the full survey results, please contact Evan Pondel at [emailprotected].

About Lane Fertility Institute

Lane Fertility Institute is a leading provider of fertility treatments focused on providing care and treatment uniquely tailored to meet the individual needs of patients. Led by Danielle Lane, M.D., and her tenured clinical team, the practice is committed to the success of its patients and providing cost-conscious care. With locations in San Francisco and Novato, California, Lane Fertility Institute provides a wide variety of treatments ranging from basic fertility care to the most advanced in vitro fertilization (IVF) technology. For more information, please visit http://lanefertilityinstitute.com.

Media Contact: Evan Pondel Triunfo Partners (818) 835-0677 [emailprotected]

SOURCE Lane Fertility Institute

Home

View post:
Nearly a Quarter of Americans 21 To 50 Years Old to Consider Having Children if Fertility Treatments Are More Affordable, Says Fertility Access Survey...

Discrimination may increase risk of anxiety disorders regardless of genetics, study finds – Tufts Now

MEDFORD/SOMERVILLE, Mass (Jan. 14, 2021) Exposure to discrimination plays a significant role in the risk of developing anxiety and related disorders, even in a first after accounting for potential genetic risks, according to a multidisciplinary team of health researchers led by Tufts University and the Harvard T.H. Chan School of Public Health.

Researchers determined that even after controlling for genetic risk for anxiety, depression, and neuroticism, greater reports of discrimination experiences remained associated with higher scores of anxiety and related disorders. The findings, recently published in Proceedings of the National Academy of Sciences, suggest that discrimination is a risk factor for anxiety and related disorders rather than solely a result of common genetic liability.

The study authors included researchers from Stony Brook University, University of Minnesota, in addition to Harvards School of Public Health and Tufts.

The study results demonstrate that discriminatory experiences can potentially cause stress and mental health problems regardless of the genetic constitution of the individual, said Adolfo G. Cuevas, an assistant professor of community health and director of the Psychosocial Determinants of Health Lab at Tufts School of Arts and Sciences, who is first author of the study. From regular slights in public spaces to more significant incidents, such as being passed over for a promotion or a loan, these experiences can take a toll on your mental health.

Anxiety disorders, including generalized anxiety disorder, panic disorder or phobias, are the most common mental illness, affecting over 40 million people in the United States every year, according to the Anxiety and Depression Association of America. While exposure to discrimination has long been established as a risk factor in the development of these disorders, the relationship between discrimination and anxiety, when factoring in the role genetics play, has remained less clear.

To gain insight on the connection, the research team used data from a national probability sample of approximately 1,500 non-institutionalized, all English-speaking adults aged 2574 and living in the mainland United States. Approximately 49 percent of the sample were women.

Three self-report scales were used to measure discrimination and other forms of social exclusion, including:

After accounting for increased genetic liability for anxiety, depression, neuroticism, and other potential genetic and sociodemographic factors, the researchers found a high degree of interdependence between discrimination and anxiety.

The team said the findings demonstrate that alleviating the impact of discrimination has the potential to improve mental health within the overall population. "Anxiety is one of the most significant issues in mental health today, and our study conclusions underscore the importance of reducing discrimination exposure and thereby improving the public's mental health overall," said the senior author of the study, Robert F. Krueger, Distinguished McKnight University Professor of Psychology at the University of Minnesota.

These findings allow us to engage in conversations with political leaders, health officials, and community members to develop functional approaches to reduce exposure to discrimination and improve the mental health of all, David R. Williams, a study co-author and theFlorence Sprague Norman and Laura Smart Norman Professor of Public Health at the Harvard T.H. Chan School of Public Health. Williams is also a professor in the department of African and African American Studies at Harvard.

The impact of anxiety disorders is significant. Symptoms are a common associated feature of depressive disorders and, generally, account for a substantial burden of morbidity and mortality as well as long-term work disability and absenteeism. For instance, anxiety disorders are associated with several chronic health conditions, including heart disease, hypertension, and diabetes.

The researchers identified key limitations of the study, including the use of a cohort of white-identifying respondents who were predominately of European ancestry. They noted while the effects of discrimination seem to be similar across racial/ethnic groups, racial/ethnic minorities experience more discrimination than their white counterparts, placing them at an increased risk for poor mental health. In addition, questions remain about the extent to which self-reported experiences of discrimination by whites are equivalent to those of more socially stigmatized groups.

The study uses data from the MIDUS (the study of Midlife in the United States Biomarker) study, which is supported by the John D. and Catherine T. MacArthur Foundation Research Network, National Institute on Aging and other funders. The development of the manuscript was partially supported by Cancer Disparities Research Network/Geographic Management Program and other supporters. See the paper for detailed information on all funders.

Cuevas, A.G., Mann, F.D., Williams, D.R., and Krueger, R. F. (2020), Discrimination and anxiety: Using multiple polygenic scores to control for genetic liability, PNAS. DOI: 20172244118

###

About Tufts University

Tufts University, located on campuses in Boston, Medford/Somerville and Grafton, Massachusetts, and in Talloires, France, is recognized among the premier research universities in the United States. Tufts enjoys a global reputation for academic excellence and for the preparation of students as leaders in a wide range of professions. A growing number of innovative teaching and research initiatives span all Tufts campuses, and collaboration among the faculty and students in the undergraduate, graduate and professional programs across the university's schools is widely encouraged.

Read this article:
Discrimination may increase risk of anxiety disorders regardless of genetics, study finds - Tufts Now

Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion – TechCrunch

Technologists are getting better at coding biology and venture firms are flooding a new generation of startups with cash so they can commercialize their technology bringing in the next wave of genetic innovation.

Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with $230 million in new financing to build up its platform for better biological programming.

The round was led by Alaska Permanent Fund Corp., Altitude Life Science Ventures and the second SoftBank Vision Fund, with participation from the Qatari Investment Authority and other undisclosed investors.

Last year, the company took the covers off its gene-writing service, which combined an array of different gene editing, manufacturing and synthesizing technologies to provide more tailored therapeutic instructions to genetic code.

By providing more instructions to genetic material, the company aims to increase the precision of therapies while expanding the number of potential pathogens or mutations they can target, the company said in a statement.

The thesis is similar to the approach taken by companies like Senti Bio, another early-stage biotech company that raised $105 million earlier this month.

The ability to write in the code of life will be a defining technology of this century and drive a fundamental change in medicine. Todays support is a testament to Tesseras outstanding team of scientists and our focus on bringing the extraordinary promise of Gene Writing to patients, said Geoffrey von Maltzahn, CEO and co-founder of Tessera Therapeutics, and a partner at Flagship Pioneering. We look forward to turning this powerful technology into a new category of medicines.

Part of a number of companies focused on gene therapies and gene-editing technologies that have been developed under the Flagship Pioneering umbrella, Tessera Therapeutics focuses on the development of new therapies that will use messenger RNA, targeted fusogenic vectors and epigenetic controllers, according to Flagship Pioneering founder and chief executive Noubar Afeyan, who also serves as the chair and co-founder of Tessera.

While Senti Bio is adding more programming to existing genetic material, Tessera uses mobile genetic elements, the most abundant genetic material in the body to create new vectors for writing and rewriting the human genome.

The company asserts that this represents a breakthrough in genetic engineering, which can build better therapies. Thats because the technology can target very specific sites in the genome to make any substitutions, insertions or deletions in genetic code. Tessera also said that its tech allows for more efficient engineering of somatic cell genomes without double stranded-breaks and with very little reliance on DNA repair pathways.

Gene writing is inspired by and builds upon the shoulders of natures most prevalent class of genes: mobile genetic elements. Tesseras computational and high-throughput laboratory platform has enabled the team to design, build and test thousands of engineered and synthetic mobile genetic elements for writing and rewriting the human genome.

The company said it can also write entirely new sequences into the genome by delivering only RNA.

With the new round of funding, Tessera said it would look to further develop its tech, hire more staff and establish manufacturing and automation capabilities critical for its platform and programs.

Follow this link:
Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion - TechCrunch

Discrimination ups anxiety risk regardless of genetics – The Tribune

New York, January 15

Regardless of genetic risks, exposure to discrimination in life plays a significant role in developing anxiety and related disorders, suggests a new study.

Published in the Proceedings of National Academy of Sciences journal, the study determined that even after controlling genetic risk for anxiety, depression and neuroticism, people reported greater discrimination experiences.

"The results demonstrate that discriminatory experiences can potentially cause stress and mental health problems regardless of the genetic constitution of the individual," said researcher Adolfo G Cuevas, an assistant professor at Tufts University in the US.

To gain insight on the connection, the research team used data from a national probability sample of nearly 1,500 non-institutionalised, all English-speaking adults between 25 to 74 years in age.

Nearly 49 per cent of the sample were women.

Three self-report scales were used to measure discrimination and other forms of social exclusion, including everyday discrimination, major discrimination and chronic job discrimination.

After accounting for increased genetic liability for anxiety, depression, neuroticism, and other potential genetic and socio-demographic factors, the researchers found a high degree of interdependence between discrimination and anxiety.

The team said the findings demonstrate that alleviating the impact of discrimination has the potential to improve mental health within the overall population. IANS

Read more from the original source:
Discrimination ups anxiety risk regardless of genetics - The Tribune

Scientists discover genetic variations that have a drastic impact on small molecules – News-Medical.Net

The human organism requires a variety of small molecules, such as sugars or fats, in order to function properly. The composition of these so-called metabolites and their interaction - the metabolism - varies from person to person and is dependent not only on external influences, such as nutrition, but also to a significant extent on natural variations in our genetic make-up.

In an international study, scientists from the Berlin Institute of Health (BIH) and Charit - Universittsmedizin Berlin joined forces with colleagues from the United Kingdom, Australia and the United States and discovered hundreds of previously unknown variations in genes that have a sometimes drastic impact on the concentration of these small molecules in the blood. The researchers have now published their findings in the journal Nature Genetics.

The concentration and composition of metabolites - small molecules in the blood or tissue fluid - provide information about biological processes in the human body. They therefore serve as important biomarkers in clinical medicine, for example in the diagnosis of diseases or in checking the effectiveness of a therapy. Interestingly, the composition of metabolites differs from person to person, independent of external influences such as illness or diet.

This is because the blueprints for the proteins that influence metabolite concentration, such as enzymes and transporter proteins, also differ between individuals. Often, the tiniest genetic variants can cause a metabolic enzyme to be more or less active or a transporter protein to be more or less efficient, thus raising or lowering the concentration of metabolites.

The team led by Claudia Langenberg, BIH Professor of Computational Medicine, has now investigated the effect of genetic variants on 174 different metabolites. "We found a surprising number of correlations between certain genetic variants and changes in the concentration of small molecules in the blood," reports the epidemiologist. "In most cases, the genetic variants cause changes in the blueprint of key metabolism regulators, like enzymes or transporters."

To explore these correlations, Langenberg's team needed huge amounts of data.

For our studies, we used large databases that gave us the blood test results and genetic information of a total of around 85,000 people. In doing so, we were able to successfully demonstrate that it is possible to jointly evaluate data from a variety of small individual studies, even across technological boundaries."

Maik Pietzner, Lead Author and Scientist in Langenberg's Laboratory

The scientists' work is highly relevant to medicine, because it can explain how naturally occurring genetic variants that influence the metabolism contribute to the onset of common diseases, such as diabetes mellitus, as well as rare diseases. For example, high levels of the amino acid serine in the blood seem to provide protection against a rare eye disease called macular telangiectasia - knowledge that opens up new therapeutic avenues.

In another study, the authors were also able to show that an individual's genetic risk for altered serine metabolism can aid in the early diagnosis of this serious eye disease. They have also identified a new mechanism that explains how the disrupted transmission of signals via the GLP-2 receptor increases the risk of developing type 2 diabetes.

"What was special about our study were the extreme effects that we observed and their potential relevance for medical research," explains Langenberg. "For example, we were able to detect genetic variants that have an influence on metabolism a good three times as strong as the already known effects of more common genetic variations, for example on body mass index."

To enable scientists around the world to link up their particular fields of expertise with their data, the team has set up an interactive website at http://www.omicscience.org. After all, Langenberg emphasizes, data is only relevant if it can also be used: "We very much hope that these compelling examples will encourage other scientists and doctors to apply our results to their specific research or disease cases."

Source:

Journal reference:

Lotta, L.A., et al. (2021) A cross-platform approach identifies genetic regulators of human metabolism and health. Nature Genetics. doi.org/10.1038/s41588-020-00751-5.

Original post:
Scientists discover genetic variations that have a drastic impact on small molecules - News-Medical.Net

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy -…

BOSTON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, and Blueprint Genetics, a Quest Diagnostics company, today announced the Resonate program. The program offers genetic testing to eligible individuals with auditory neuropathy at no cost to participants, their insurance, or their healthcare providers.

Every year, thousands of children are born with disabling hearing loss and the majority of cases of congenital hearing loss are due to an underlying genetic cause. However, few individuals receive a genetic diagnosis and a key barrier is the availability and accessibility of genetic testing. The Resonate program seeks to overcome the barriers to genetic testing for individuals with auditory neuropathy, empower them to make informed choices, and provide potentially valuable insight to inform medical management.

Akouos is committed to deepening the community's understanding of the genetic forms of auditory neuropathy, a type of sensorineural hearing loss. Today, there are no pharmacologic therapies approved for the treatment of hearing loss. The development of new therapeutic options for underserved patient populations has become increasingly reliant on identification of the underlying genetic cause of a genetic disease, disorder, or condition, said Manny Simons, Ph.D., founder, president, and CEO of Akouos. We hope the Resonate program, along with our efforts to better understand the genetic causes and natural history of multiple forms of sensorineural hearing loss, will enable the research and development of novel genetic medicines for individuals with disabling hearing loss.

There are many different genetic changes that cause hearing loss. These changes can be complex and difficult for routine genetic testing to detect. Understanding the genetic cause of hearing loss requires a high-quality genetic testing strategy that includes the mitochondrial genome, difficult-to-sequence genes, and deep intronic variants in addition to copy number variants in order to increase the diagnostic potential for the program participant. We are excited to work with Akouos to offer our comprehensive genetic testing approach to individuals with auditory neuropathy, says Tero-Pekka Alastalo, M.D., Ph.D., executive medical director of Blueprint Genetics.

The Resonate program is available in the United States and plans to expand to additional geographic regions throughout 2021. To be eligible for the program, individuals can be any age, and must have a current or prior clinical diagnosis of auditory neuropathy, or a medical history consistent with auditory neuropathy. Auditory neuropathy is a hearing disorder in which the inner ear successfully detects sound, but has a problem with sending sound from the ear to the brain.In many cases, genetic mutations cause auditory neuropathy. The Resonate program provides access to the Blueprint Genetics Comprehensive Hearing Loss and Deafness Panel that includes more than 230 genes associated with genetic forms of hearing loss. To help understand their results, participants in the United States also have access to genetic counseling provided by the program at no cost to participants, their insurance, or their healthcare providers.

For more information on the Resonate program, individuals and families please visit http://www.akouosresonate.com and healthcare providers please visit http://www.blueprintgenetics.com/resonate-program.

About AkouosAkouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. http://www.akouos.com

About Blueprint GeneticsBlueprint Genetics, a Quest Diagnostics company, is a leading specialty genetics and bioinformatics company focused on providing genetic testing for inherited diseases. The company is based in Helsinki and Seattle, with a customer base spanning over 70 countries.www.blueprintgenetics.com

Cautionary Note Regarding Akouos Forward-Looking StatementsStatements in this press release about Akouoss future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expectations for the Resonate program and the roll-out of the Resonate program. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Akouoss plans to develop and, if approved, subsequently commercialize Akouoss product candidates; the timing of and Akouoss ability to submit applications for, and obtain and maintain regulatory approvals for, Akouoss product candidates; Akouoss expectations regarding Akouoss regulatory strategy; Akouoss expectations regarding Akouoss ability to fund Akouoss operating expenses and capital expenditure requirements with Akouoss cash, cash equivalents and marketable securities; the potential advantages of Akouoss product candidates; the rate and degree of market acceptance and clinical utility of Akouoss product candidates; Akouoss estimates regarding the potential addressable patient population for Akouoss product candidates; Akouoss commercialization, marketing and manufacturing capabilities and strategy; Akouoss expectations regarding Akouoss ability to obtain and maintain intellectual property protection for Akouoss product candidates; Akouoss intellectual property position; Akouoss ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with Akouoss commercial objectives; the impact of government laws and regulations; Akouoss competitive position and expectations regarding developments and projections relating to Akouoss competitors and any competing therapies that are or become available; developments and expectations regarding developments and projections relating to Akouoss competitors and Akouoss industry; the impact of the COVID-19 pandemic on Akouoss business, results of operations, and financial condition; Akouoss ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the Risk Factors included in Akouoss Quarterly Report on Form 10-Q for the three months ended September 30, 2020 filed with the Securities and Exchange Commission, and in other filings that Akouos makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Akouos expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Akouos

Media:Katie Engleman, 1ABkatie@1abmedia.com

Investors:Courtney Turiano, Stern Investor RelationsCourtney.Turiano@sternir.com

Blueprint Genetics

Tero-Pekka Alastalo, executive medical directortpa@blueprintgenetics.com

Saara Salonoja, communication specialistsaara.salonoja@blueprintgenetics.com

Here is the original post:
Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy -...